In early and intermediate-stage rectal cancer patients choosing organ preservation, 12-month TME-free survival was 78.5% with long-course chemoradiotherapy vs 60.6% with short-course radiotherapy (HR 1.90) in an early analysis; the 30-month primary endpoint is awaited.
RCTn = 409
Bach et al. Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial